Table 1.
Current FDA-Approved Immune Checkpoint Inhibitor Indications and Trial Representation of Older Adults
| Current FDA-Approved ICI Indications (supporting trial, % ≥ 65 enrolled) | ||
|---|---|---|
| PD-1 Inhibitors | Nivolumab |
Recurrent or Metastatic Squamous Cell
Carcinoma of the Head and Neck (CHECKMATE-141+&,
31%) Metastatic NSCLC (CHECKMATE-017+&, 44%; CHECKMATE-057+&, 42%) SCLC (CHECKMATE-032*&, 45%) Hepatocellular Carcinoma (CHECKMATE-040*, 46%) dMMR or MSI-H Metastatic Colorectal Cancer (CHECKMATE-142*&, 23%) Advanced Renal Cell Carcinoma Previously Treated (CHECKMATE-025+&, 37%) Urothelial Carcinoma (CHECKMATE-275*&, 55%) Metastatic Melanoma Previously Treated (CHECKMATE-037*, not-reported) Metastatic Melanoma Previously Untreated (CHECKMATE-066#&, 52%; CHECKMATE-067+&, 37%) Adjuvant Treatment of Melanoma (CHECKMATE-238#, 26%) Classical Hodgkin Lymphoma (CHECKMATE-205*, <9%; CHECKMATE-039*, not reported) |
| Pembrolizumab |
Squamous Cell Carcinoma of the Head
and Neck (KEYNOTE-012*, 32%) Metastatic NSCLC Previously Untreated (KEYNOTE-189+, 49%; KEYNOTE-407+, 54%; KEYNOTE-024#, 54%) Metastatic NSCLC Previously Treated (KEYNOTE-010+, 42%) Gastric Cancer (KEYNOTE-059*, 47%) Hepatocellular Carcinoma (KEYNOTE-224*, 67%) dMMR or MSI-H Solid Tumors (KEYNOTE-016, -164, -012, -028, -158; 36%) Urothelial Carcinoma (KEYNOTE-052#&, 82%; KEYNOTE-045#, 58%) Cervical Cancer (KEYNOTE-158*, not-reported) Melanoma (KEYNOTE-006#, 43%; KEYNOTE-002+, 43%) Merkel Cell Carcinoma (KEYNOTE-017*, 80%) Classical Hodgkin Lymphoma (KEYNOTE-087*, 9%) Primary Mediastinal Large B-Cell Lymphoma (KEYNOTE-170*, not-reported) |
|
| PD-L1 Inhibitors | Atezolizumab |
Metastatic NSCLC
(IMpower150+&, 46%; OAK#, 47%) Locally Advanced or Metastatic Urothelial Carcinoma (IMvigor210 Cohort 1*&, 83%; IMvigor 210 Cohort 2*, not-reported) |
| Avelumab |
Locally Advanced or Metastatic
Urothelial Carcinoma (JAVELIN Solid Tumor Trial#&,
69%) Metastatic Merkel Cell Carcinoma (JAVELIN Merkel 200 Trial*, not-reported) |
|
| Durvalumab |
NSCLC (PACIFIC+&,
45%) Urothelial Carcinoma ( NCT01693562*, 62%) |
|
| CTLA-4 Inhibitor | Ipilimumab |
Unresectable or Metastatic
Melanoma (MDX010-20#, 28%) Adjuvant Treatment of Melanoma (CA184-029*, 17%) |
| Combination Regimens | Ipilimumab + Nivolumab |
dMMR or MSI-H Metastatic Colorectal
Cancer (CHECKMATE-142*&, 32%) Advanced Renal Cell Carcinoma Previously Untreated (CHECKMATE-214+&, 38%) Metastatic Melanoma Previously Untreated (CHECKMATE-067+&, 41%) |
*
Insufficient enrollment to determine if statistical difference regarding PFS or OS between age groups existed or not published
#
No reported statistical difference in PFS or OS between age groups in supporting trial
+
Reported statistical difference in PFS or OS between analyzed age groups in supporting trial
&
Included sub-group ≥ 75 either in primary publication or manufacturer’s prescribing guide